KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Return on Equity (2016 - 2025)

Historic Return on Equity for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q4 2025 value amounting to 0.54%.

  • Alnylam Pharmaceuticals' Return on Equity rose 61400.0% to 0.54% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.54%, marking a year-over-year increase of 61400.0%. This contributed to the annual value of 0.73% for FY2025, which is 28900.0% down from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Return on Equity stood at 0.54% for Q4 2025, which was up 61400.0% from 0.34% recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Return on Equity ranged from a high of 10.02% in Q4 2022 and a low of 22.69% during Q3 2024
  • For the 5-year period, Alnylam Pharmaceuticals' Return on Equity averaged around 1.91%, with its median value being 0.95% (2021).
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Return on Equity surged by 235900bps in 2023, and later crashed by -244700bps in 2024.
  • Alnylam Pharmaceuticals' Return on Equity (Quarter) stood at 1.27% in 2021, then skyrocketed by 889bps to 10.02% in 2022, then crashed by -77bps to 2.28% in 2023, then tumbled by -346bps to 5.59% in 2024, then soared by 110bps to 0.54% in 2025.
  • Its Return on Equity was 0.54% in Q4 2025, compared to 0.34% in Q3 2025 and 1.53% in Q2 2025.